Factors Implicated for Delay of Adjuvant Chemotherapy in Colorectal Cancer: A Meta-analysis of Observational Studies

Annals of Surgical Oncology

Volumn 22, Issue 12, 2015, Pages 3793-3802

  Malietzis, George ^a,b   Mughal, Aamer ^b   Currie, Andrew C ^a,b   Anyamene, Nicola ^c   Kennedy, Robin H ^a,b   Athanasiou, Thanos ^b   Jenkins, John T ^a,b  

^a ST MARK S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; AGE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COLORECTAL CANCER; COMORBIDITY; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; INTERMETHOD COMPARISON; LAPAROSCOPIC SURGERY; LENGTH OF STAY; MARRIAGE; META ANALYSIS; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; REVIEW; SEX DIFFERENCE; SOCIAL STATUS; SURGICAL APPROACH; SYSTEMATIC REVIEW; THERAPY DELAY; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; ADJUVANT CHEMOTHERAPY; CANCER GRADING; COLORECTAL NEOPLASMS; LAPAROSCOPY; OBSERVATIONAL STUDY; PATHOLOGY; SOCIAL CLASS; SOCIOECONOMICS; TIME FACTOR;

AGE FACTORS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMORBIDITY; HUMANS; LAPAROSCOPY; LENGTH OF STAY; MARITAL STATUS; NEOPLASM GRADING; OBSERVATIONAL STUDIES AS TOPIC; PATIENT READMISSION; SOCIAL CLASS; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 84943357132     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4479-2     Document Type: Review

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. (2011);61(2):69–90. doi:10.3322/caac.20107.
2. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–502. doi:10.1016/S0140-6736(13)61649-9.
3. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–9. doi:10.1016/S0140-6736(07)61866-2.
4. Bosset J-F, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23. doi:10.1056/NEJMoa060829.
5. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 1989;49(8):1996–2001. http://www.ncbi.nlm.nih.gov/pubmed/2702641. Accessed 5 Aug 2014.
6. Colorectal cancer | Guidance and guidelines | NICE. http://www.nice.org.uk/guidance/cg131. Accessed 30 Oct 2014.
7. ®) - National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/rectal/HealthProfessional/page4. Accessed 30 Oct 2014.
8. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011;305(22):2335–42. doi:10.1001/jama.2011.749.
9. Mayer EK, Chow A, Vale JA, Athanasiou T. Appraising the quality of care in surgery. World J Surg. 2009;33(8):1584–93. doi:10.1007/s00268-009-0065-8.
10. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 6 Aug 2014.
11. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2127453&tool=pmcentrez&rendertype=abstract. Accessed 8 Nov 2014.
12. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–12. http://www.ncbi.nlm.nih.gov/pubmed/10789670. Accessed 11 July 2014.
13. Strouch MJ, Zhou G, Fleshman JW, Birnbaum EH, Hunt SR, Mutch MG. Time to initiation of postoperative chemotherapy: an outcome measure for patients undergoing laparoscopic resection for rectal cancer. Dis Colon Rectum. 2013;56(8):945–51. doi:10.1097/DCR.0b013e318290ce30.
14. Simpson GS, Smith R, Sutton P, et al. The aetiology of delay to commencement of adjuvant chemotherapy following colorectal resection. Int J Surg Oncol. 2014;2014:670212. doi:10.1155/2014/670212.
15. Hendren S, Birkmeyer JD, Yin H, Banerjee M, Sonnenday C, Morris AM. Surgical complications are associated with omission of chemotherapy for stage III colorectal cancer. Dis Colon Rectum. 2010;53(12):1587–93. doi:10.1007/DCR.0b013e3181f2f202.
16. Tsai W-S, Hsieh P-S, Yeh C-Y, et al. Impact of chemotherapy-related prognostic factors on long-term survival in patients with stage III colorectal cancer after curative resection. Int J Clin Oncol. 2013;18(2):242–53. doi:10.1007/s10147-011-0370-8.
17. Ahmed S, Ahmad I, Zhu T, et al. Early discontinuation but not the timing of adjuvant therapy affects survival of patients with high-risk colorectal cancer: a population-based study. Dis Colon Rectum. 2010;53(10):1432–8. doi:10.1007/DCR.0b013e3181e78815.
18. Bayraktar UD, Chen E, Bayraktar S, et al. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma? Cancer. 2011;117(11):2364–70. doi:10.1002/cncr.25720.
19. Berglund A, Cedermark B, Glimelius B. Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III? Ann Oncol. 2008;19(2):400–2. doi:10.1093/annonc/mdm582.
20. Cheung WY, Neville B, Earle CC. Etiology of delays in the initiation of adjuvant chemotherapy and their impact on outcomes for Stage II and III rectal cancer. Dis Colon Rectum. 2009;52(6):1054–63. doi:10.1007/DCR.0b013e3181a51173.
21. Czaykowski PM, Gill S, Kennecke HF, Gordon VL, Turner D. Adjuvant chemotherapy for stage III colon cancer: does timing matter? Dis Colon Rectum. 2011;54(9):1082–9. doi:10.1097/DCR.0b013e318223c3d6.
22. Day AR, Middleton G, Smith RVP, Jourdan IC, Rockall TA. Time to adjuvant chemotherapy following colorectal cancer resection is associated with an improved survival. Colorectal Dis. 2014;16(5):368–72. doi:10.1111/codi.12570.
23. Hershman D, Hall MJ, Wang X, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer. 2006;107(11):2581–8. doi:10.1002/cncr.22316.
24. Lima ISF, Yasui Y, Scarfe A, Winget M. Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada. Cancer. 2011;117(16):3833–40. doi:10.1002/cncr.25954.
25. Merkow RP, Bentrem DJ, Mulcahy MF, et al. Effect of postoperative complications on adjuvant chemotherapy use for stage III colon cancer. Ann Surg. 2013;258(6):847–53. doi:10.1097/SLA.0000000000000312.
26. Rayson BD, Urquhart R, Cox M, Grunfeld E. Original contribution adherence to clinical practice guidelines for adjuvant chemotherapy for colorectal cancer in a Canadian Province: a population-based analysis. J Oncol Pract. 2012;1:253–260.
27. Tevis SE, Kohlnhofer BM, Stringfield S, et al. Postoperative complications in patients with rectal cancer are associated with delays in chemotherapy that lead to worse disease-free and overall survival. Dis Colon Rectum. 2013;56(12):1339–48. doi:10.1097/DCR.0b013e3182a857eb.
28. Van der Geest LGM, Portielje JEA, Wouters MWJM, et al. Complicated postoperative recovery increases omission, delay and discontinuation of adjuvant chemotherapy in patients with Stage III colon cancer. Colorectal Dis. 2013;15(10):e582–91. doi:10.1111/codi.12288.
29. Gantt G, Ashburn J, Kiran RP, Khorana A, Kalady MF. Laparoscopy mitigates adverse oncological effects of delayed adjuvant chemotherapy for colon cancer. Surg Endosc. 2014. doi:10.1007/s00464-014-3697-1.
30. Yu S, Shabihkhani M, Yang D, et al. Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. Clin Colorectal Cancer. 2013;12(4):275–9. doi:10.1016/j.clcc.2013.08.002.
31. Massarweh NN, Haynes AB, Chiang Y-J, et al. Adequacy of the National Quality Forum’s Colon Cancer Adjuvant Chemotherapy Quality Metric: Is 4 months soon enough? Ann Surg. 2014. doi:10.1097/SLA.0000000000000859.
32. Hensler T, Hecker H, Heeg K, et al. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun. 1997;65(6):2283–91. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=175317&tool=pmcentrez&rendertype=abstract. Accessed 5 Aug 2014.
33. Harless W, Qiu Y. Cancer: A medical emergency. Med Hypotheses. 2006;67(5):1054–9. doi:10.1016/j.mehy.2006.04.032.
34. Shahir MA, Lemmens VEPP, van de Poll-Franse L V, Voogd AC, Martijn H, Janssen-Heijnen MLG. Elderly patients with rectal cancer have a higher risk of treatment-related complications and a poorer prognosis than younger patients: a population-based study. Eur J Cancer. 2006;42(17):3015–21. doi:10.1016/j.ejca.2005.10.032.
35. Surgery for colorectal cancer in elderly patients: a systematic review. Colorectal Cancer Collaborative Group. Lancet. 2000;356(9234):968-74. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11041397. Accessed 7 Aug 2014.
36. Esteva M, Ruiz A, Ramos M, et al. Age differences in presentation, diagnosis pathway and management of colorectal cancer. Cancer Epidemiol. 2014;38(4):346–53. doi:10.1016/j.canep.2014.05.002.
37. Kennedy RH, Francis EA, Wharton R, et al. Multicenter Randomized Controlled Trial of Conventional Versus Laparoscopic Surgery for Colorectal Cancer Within an Enhanced Recovery Programme: EnROL. J Clin Oncol. 2014. doi:10.1200/JCO.2013.54.3694.
38. Chan A, Woods R, Kennecke H, Gill S. Factors associated with delayed time to adjuvant chemotherapy in stage iii colon cancer. Curr Oncol. 2014;21(4):181–6. doi:10.3747/co.21.1963.
39. Malietzis G, Scuppa D, Nachiappan S, et al. Myopenia is associated with delay and failure to transition to adjuvant chemotherapy in stage III colorectal cancer: P241. Color Dis. 2014.
40. Malietzis G. Giacometti M. Lee G.H. Kennedy R.H. Glynne-Jones R. Anyamene N. Aziz O. Jenkins J.T. Preoperative neutrophil to lymphocyte ratio independently predicts failure to proceed with adjuvant chemotherapy in stage III colorectal cancer. 2013:S507. doi:10.1016/S0959.
41. Borras JM, Albreht T, Audisio R, et al. Policy statement on multidisciplinary cancer care. Eur J Cancer. 2014;50(3):475–80. doi:10.1016/j.ejca.2013.11.012.
42. Popescu RA, Schäfer R, Califano R, et al. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol. 2014;25(1):9–15. doi:10.1093/annonc/mdt522.